Focused Alpha LLC Makes New $472,000 Investment in Natera, Inc. $NTRA

Posted by Stanley Muller on Aug 18th, 2026

Focused Alpha LLC bought a new stake in Natera, Inc. (NASDAQ:NTRA – Free Report) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 1,738 shares of the medical research company’s stock, valued at approximately $472,000.

Several other hedge funds have also modified their holdings of the stock. BlackRock Inc. acquired a new position in shares of Natera in the 2nd quarter valued at approximately $2,962,770,000. Coatue Management LLC increased its stake in shares of Natera by 1,446.1% in the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock worth $603,270,000 after buying an additional 2,463,008 shares during the last quarter. Wellington Management Group LLP raised its holdings in Natera by 94.7% in the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after acquiring an additional 2,420,263 shares in the last quarter. Norges Bank bought a new position in Natera during the 4th quarter valued at $372,398,000. Finally, JPMorgan Chase & Co. grew its holdings in Natera by 10.5% during the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock worth $2,944,800,000 after acquiring an additional 1,225,420 shares in the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on NTRA shares. Canaccord Genuity Group set a $375.00 target price on shares of Natera in a research note on Friday, August 7th. Piper Sandler upped their price objective on Natera from $249.00 to $363.50 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. BTIG Research lifted their target price on Natera from $290.00 to $320.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Wall Street Zen downgraded Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Finally, UBS Group set a $260.00 price objective on Natera in a research note on Wednesday, June 24th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $319.38.

Read Our Latest Report on NTRA

Natera Trading Up 1.4%

Shares of Natera stock opened at $314.18 on Tuesday. The stock has a market capitalization of $45.29 billion, a price-to-earnings ratio of -231.01 and a beta of 1.51. Natera, Inc. has a twelve month low of $156.71 and a twelve month high of $326.03. The business’s 50 day simple moving average is $265.78 and its 200-day simple moving average is $226.82.

Natera (NASDAQ:NTRA – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. The firm had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.During the same period in the prior year, the business earned ($0.74) EPS. The firm’s revenue was up 37.7% on a year-over-year basis. Sell-side analysts predict that Natera, Inc. will post -1.11 earnings per share for the current year.

Insider Activity

In other Natera news, insider John Fesko sold 295 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $267.99, for a total value of $79,057.05. Following the completion of the transaction, the insider owned 183,774 shares in the company, valued at approximately $49,249,594.26. This represents a 0.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Burkes Brophy sold 478 shares of the firm’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $274.22, for a total transaction of $131,077.16. Following the completion of the sale, the chief financial officer owned 51,637 shares in the company, valued at $14,159,898.14. The trade was a 0.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 181,045 shares of company stock valued at $41,330,968. 5.05% of the stock is owned by company insiders.

Natera Company Profile

(Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.